Nancy Stuart Net Worth

The estimated Net Worth of Nancy Stuart is at least $4.92 Milion dollars as of 15 February 2023. Ms. Stuart owns over 6,048 units of Concert Pharmaceuticals Inc stock worth over $2,197,929 and over the last 10 years she sold CNCE stock worth over $815,155. In addition, she makes $1,908,030 as Chief Operating Officer at Concert Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Stuart CNCE stock SEC Form 4 insiders trading

Nancy has made over 20 trades of the Concert Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently she sold 6,048 units of CNCE stock worth $50,380 on 15 February 2023.

The largest trade she's ever made was exercising 48,882 units of Concert Pharmaceuticals Inc stock on 25 January 2018 worth over $223,880. On average, Nancy trades about 8,152 units every 86 days since 2014. As of 15 February 2023 she still owns at least 262,596 units of Concert Pharmaceuticals Inc stock.

You can see the complete history of Ms. Stuart stock trades at the bottom of the page.

Nancy Stuart biography

Nancy Stuart serves as Chief Operating Officer of the Company. Ms. Stuart has served as our Chief Operating Officer since October 2007 and was our Senior Vice President, Corporate Strategy and Operations from July 2006 to October 2007. Prior to joining Concert, Ms. Stuart held various business operations and business development positions at Amgen Inc., a biopharmaceutical company, Kinetix Pharmaceuticals, Inc., a pharmaceutical company subsequently acquired by Amgen, Scion Pharmaceuticals, Inc., a pharmaceutical company, Vertex Pharmaceuticals Incorporated, a pharmaceutical company, and Genzyme Corporation, a biotechnology company. Ms. Stuart received a B.S. from the University of Michigan and an M.B.A. from the Simmons College Graduate School of Management.

What is the salary of Nancy Stuart?

As the Chief Operating Officer of Concert Pharmaceuticals Inc, the total compensation of Nancy Stuart at Concert Pharmaceuticals Inc is $1,908,030. There are 1 executives at Concert Pharmaceuticals Inc getting paid more, with Roger Tung having the highest compensation of $2,772,350.

How old is Nancy Stuart?

Nancy Stuart is 62, she's been the Chief Operating Officer of Concert Pharmaceuticals Inc since 2007. There are 7 older and 8 younger executives at Concert Pharmaceuticals Inc. The oldest executive at Concert Pharmaceuticals Inc is Peter Hutt, 85, who is the Independent Director.

What's Nancy Stuart's mailing address?

Nancy's mailing address filed with the SEC is C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE, MA, 02142.

Insiders trading at Concert Pharmaceuticals Inc

Over the last 11 years, insiders at Concert Pharmaceuticals Inc have traded over $69,766,120 worth of Concert Pharmaceuticals Inc stock and bought 1,926,078 units worth $25,219,472 . The most active insiders traders include Plc Gsk, Associates Gp Llcqvt Fund V... oraz Partners L P/Ilbiotechnolog.... On average, Concert Pharmaceuticals Inc executives and independent directors trade stock every 28 days with the average trade being worth of $447,820. The most recent stock trade was executed by Nancy Stuart on 15 February 2023, trading 6,048 units of CNCE stock currently worth $50,380.

What does Concert Pharmaceuticals Inc do?

Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert's lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates.

Complete history of Ms. Stuart stock trades at Concert Pharmaceuticals Inc i KalVista Pharmaceuticals Inc

Concert Pharmaceuticals Inc executives and stock owners

Concert Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Roger Tung,
  President, Chief Executive Officer, Co-Founder, Director
• Nancy Stuart,
  Chief Operating Officer
• Marc Becker,
  Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer
• James Cassella,
  Chief Development Officer
• Dr. Roger D. Tung,
  Co-Founder, CEO, Pres & Exec. Director
• Dr. James V. Cassella,
  Chief Devel. Officer
• Jesper Hoiland,
  Independent Director
• Richard Aldrich,
  Independent Chairman of the Board, Co-Founder
• Thomas Auchincloss,
  Independent Director
• Ronald Barrett,
  Independent Director
• Peter Hutt,
  Independent Director
• Christine van Heek,
  Independent Director
• Wilfred Jaeger,
  Independent Director
• Richard H. Aldrich M.B.A., Mba,
  Co-Founder & Chairman
• Justine Koenigsberg,
  Senior Vice President, Corporate Communications and Investor Relations
• Jeffrey Munsie,
  Chief Legal Officer, Secretary
• Christine Boisclair,
  Sr. VP of Regulatory Affairs & Quality Assurance
• Dr. Nabil Uddin Pharm.D.,
  VP of Corp. Devel.
• Jeffrey A. Munsie,
  Chief Legal Officer & Corp. Sec.
• Marc A. Becker,
  CFO & Principal Accounting Officer
• Nancy Stuart,
  Chief Operating Officer
• Wendall Wierenga,
  Director
• Wilfred Ethree Arch Managem...,
  
• Pauline Mc Gowan,
  VP, Finance
• D. Ryan Daws,
  Chief Financial Officer
• Robert Silverman,
  Senior VP, General Counsel
• Meghan Fitzgerald,
  Director
• Lynette Herscha,
  General Counsel
• Heek Christi Van,
  Director
• Ryan Lynch,
  PAO
• Partners L P/Ilbiotechnolog...,
  
• Leaf Ventures I, L.P.New Le...,
  
• Helmut Schuhsler,
  Director
• John Gordon Freund,
  Director
• Associates Gp Llcqvt Fund V...,
  
• Capital Management Llcbrook...,
  
• Ventures Fund 2004 L P Flag...,
  
• Plc Gsk,
  
• Capital Partners, L.P.Adage...,
  
• Venture Partners Qualified ...,
  
• Life Science Ventures Vi Gm...,
  
• Arch Management Iv, L.L.C.J...,
  
• Arch Management Iii Llcthre...,
  
• Arch Management Iv, L.L.C.J...,
  
• Xii Gp Llc Greylock Xii Lim...,
  
• Arch Management Iii Llcjaeg...,
  
• Jesper Hoeiland,
  Director
• Marc A. Becker,
  Chief Financial Officer